- Home
- RCS vs HRTX Comparison
RCS vs HRTX Comparison
Compare RCS & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- HRTX
- Stock Information
- Founded
- RCS 1994
- HRTX 1983
- Country
- RCS United States
- HRTX United States
- Employees
- RCS N/A
- HRTX N/A
- Industry
- RCS Investment Managers
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- HRTX Health Care
- Exchange
- RCS Nasdaq
- HRTX Nasdaq
- Market Cap
- RCS 292.8M
- HRTX 270.7M
- IPO Year
- RCS N/A
- HRTX 1987
- Fundamental
- Price
- RCS $6.29
- HRTX $2.48
- Analyst Decision
- RCS
- HRTX Strong Buy
- Analyst Count
- RCS 0
- HRTX 3
- Target Price
- RCS N/A
- HRTX $5.67
- AVG Volume (30 Days)
- RCS 141.1K
- HRTX 2.7M
- Earning Date
- RCS 01-01-0001
- HRTX 05-06-2025
- Dividend Yield
- RCS 10.12%
- HRTX N/A
- EPS Growth
- RCS N/A
- HRTX N/A
- EPS
- RCS N/A
- HRTX N/A
- Revenue
- RCS N/A
- HRTX $144,285,000.00
- Revenue This Year
- RCS N/A
- HRTX $11.81
- Revenue Next Year
- RCS N/A
- HRTX $15.79
- P/E Ratio
- RCS N/A
- HRTX N/A
- Revenue Growth
- RCS N/A
- HRTX 13.57
- 52 Week Low
- RCS $4.51
- HRTX $1.04
- 52 Week High
- RCS $6.31
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- RCS 46.02
- HRTX 63.83
- Support Level
- RCS $6.21
- HRTX $2.29
- Resistance Level
- RCS $6.32
- HRTX $2.45
- Average True Range (ATR)
- RCS 0.14
- HRTX 0.25
- MACD
- RCS 0.01
- HRTX 0.01
- Stochastic Oscillator
- RCS 41.67
- HRTX 76.19
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.